肺炎链球菌疫苗市场：按疫苗类型（肺炎链球菌结合疫苗、肺炎链球菌多醣体疫苗）、目标人口、按给药途径、按分销管道、按地区

预计2024年全球肺炎链球菌疫苗市场规模为89.2亿美元，预计2031年将达到125.1亿美元，2024年至2031年复合年增长率为4.9%。

图：2024 年按地区分類的肺炎链球菌疫苗市场占有率(%)

全球肺炎球菌疫苗市场的成长是由全球肺炎球菌疾病盛行率上升和政府加强免疫计划等因素所推动的。此外，人们对肺炎球菌疫苗接种的认识不断提高也推动了市场的成长。然而，肺炎球菌疫苗开发和生产的高成本可能会阻碍市场成长。持续研究和开发负担得起且有效的疫苗可能会在不久的将来提供新的机会。

市场动态：

全球肺炎链球菌疫苗市场的成长主要是由全球肺炎球菌肺炎、脑膜炎和其他严重感染疾病盛行率上升所推动的。据世界卫生组织(WHO)称，肺炎是5岁以下儿童死亡的前五位原因之一。此外，增加政府资金和透过国家免疫计划促进免疫计划的倡议可能会推动市场成长。然而，肺炎链球菌疫苗高昂的研发和製造成本可能会阻碍市场扩张。正在进行的评估新型多效价肺炎链球菌製剂的安全性和有效性的临床试验可能会推动市场成长。新兴国家拥有发达的医疗基础设施，为市场进入者提供了巨大的机会。

本研究的主要特点

本报告对全球肺炎球菌疫苗市场进行了详细分析，并列出了以2023年为基准年的预测期（2024-2031年）的市场规模和年均增长率。

它还揭示了各个细分市场的潜在商机，并解释了该市场中有吸引力的投资提案的矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。

根据公司亮点、产品系列、主要亮点、绩效和策略等参数，包括全球肺炎链球菌疫苗市场的主要企业概况。

主要公司包括辉瑞公司、默克公司、葛兰素史克公司和赛诺菲公司。

本报告中的见解将帮助负责人和公司经营团队就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。

全球肺炎球菌疫苗市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

目录

第一章 研究目的与前提

• 研究目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章 市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 主要亮点
• 监管场景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景

第四章全球肺炎链球菌疫苗市场，依疫苗类型，2019-2031

• 肺炎链球菌结合疫苗 (PCV)
• 肺炎链球菌多醣体疫苗（PPV）

第五章全球肺炎链球菌疫苗市场，依目标人口，2019-2031

• 成人（65岁以上）
• 儿童（5岁以下）
• 高危险群成人（18-64 岁）

第六章 全球肺炎链球菌疫苗市场，依给药途径，2019-2031 年

• 肌肉注射
• 皮下的

第7章全球肺炎链球菌疫苗市场，依通路，2019-2031

• 医院药房
• 零售药房
• 网路药房

第八章全球肺炎链球菌疫苗市场，按地区，2019-2031

• 拉丁美洲
• 欧洲
• 亚太地区
• 中东

第9章 竞争格局

• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc（GSK）
• Sanofi
• CSL Limited
• Serum Institute of India Pvt. Ltd.
• Vaxcyte, Inc.
• Astellas Pharma Inc.
• Panacea Biotec Ltd.
• Walvax Biotechnology Co., Ltd.
• Beijing Minhai Biotechnology Co., Ltd.
• Merck KGaA
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Novartis AG
• Johnson & Johnson
• Biovac
• Bharat Biotech
• Inovio Pharmaceuticals, Inc.
• Hilleman Laboratories Pvt. Ltd

第10章分析师建议

• 命运之轮
• 分析师观点
• 一致的机会图

第十一章 参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Global pneumococcal vaccines market is estimated to be valued at USD 8.92 billion in 2024 and is expected to reach USD 12.51 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.

Figure. Pneumococcal Vaccines Market Share (%), By Region 2024

Global pneumococcal vaccines market growth is driven by factors such as rising incidence of pneumococcal diseases worldwide and growing immunization programs by various governments. Moreover, increasing awareness among people regarding pneumococcal vaccination can also drive the market growth. However, high costs associated with pneumococcal vaccines development and production can hamper the market growth. Ongoing research activities for developing affordable and effective vaccines can offer new opportunities in the near future.

Market Dynamics:

Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.

Key features of the study:

This report provides in-depth analysis of the global pneumococcal vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pneumococcal vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Merck & Co., GSK plc., and Sanofi

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global pneumococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

• By Vaccine Type
  • Pneumococcal Conjugate Vaccines (PCVs)
  • PCV13 (Prevnar 13/Prevenar 13)
  • PCV10 (Synflorix)
  • PCV7 (Prevnar/Prevenar)
  • Pneumococcal Polysaccharide Vaccines (PPVs)
  • PPSV23 (Pneumovax 23)
  • PPSV14 (Pneumo 14)
• By Target Population
  • Adults (>= 65 years)
  • Children (< 5 years)
  • High-Risk Adults (18-64 years)
• By Route of Administration
  • Intramuscular
  • Subcutaneous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Key Players Insights
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • Sanofi
  • CSL Limited
  • Serum Institute of India Pvt. Ltd.
  • Vaxcyte, Inc.
  • Astellas Pharma Inc.
  • Panacea Biotec Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd.
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Biovac
  • Bharat Biotech
  • Inovio Pharmaceuticals, Inc.
  • Hilleman Laboratories Pvt. Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Pneumococcal Vaccines Market, By Vaccine Type
  • Global Pneumococcal Vaccines Market, By Target Population
  • Global Pneumococcal Vaccines Market, By Route of Administration
  • Global Pneumococcal Vaccines Market, By Distribution Channel
  • Global Pneumococcal Vaccines Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Pneumococcal Vaccines Market, By Vaccine Type, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Pneumococcal Conjugate Vaccines (PCVs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • PCV13 (Prevnar 13/Prevenar 13)
  • PCV10 (Synflorix)
  • PCV7 (Prevnar/Prevenar)
• Pneumococcal Polysaccharide Vaccines (PPVs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • PPSV23 (Pneumovax 23)
  • PPSV14 (Pneumo 14)

5. Global Pneumococcal Vaccines Market, By Target Population, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Adults (>= 65 years)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Children (< 5 years)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• High-Risk Adults (18-64 years)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Pneumococcal Vaccines Market, By Route of Administration, 2019-2031, (USD Bn)

• Intramuscular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Subcutaneous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Pneumococcal Vaccines Market, By Distribution Channel, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Pneumococcal Vaccines Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2020- 2031, (USD Bn)
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country/Sub-region, 2019 - 2031, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc (GSK)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• CSL Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Serum Institute of India Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Vaxcyte, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Astellas Pharma Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Panacea Biotec Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Walvax Biotechnology Co., Ltd.
• Beijing Minhai Biotechnology Co., Ltd.
• Merck KGaA
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Novartis AG
• Johnson & Johnson
• Biovac
• Bharat Biotech
• Inovio Pharmaceuticals, Inc.
• Hilleman Laboratories Pvt. Ltd

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us